Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
Liao, Weiting; Huang, Jiaxing; Hutton, David; Zhu, Guiqi; Wu, Qiuji; Wen, Feng; Bai, Liangliang; Li, Qiu.
Afiliação
  • Liao W; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Huang J; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
  • Hutton D; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Zhu G; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
  • Wu Q; Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
  • Wen F; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Bai L; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Li Q; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Liver Int ; 39(12): 2408-2416, 2019 12.
Article em En | MEDLINE | ID: mdl-31544330
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Hepatocelular / Anilidas / Neoplasias Hepáticas Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Hepatocelular / Anilidas / Neoplasias Hepáticas Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China